Search

Author/Creator Neuwirth, R.

1. 354 Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer. (September 2015)

Authors:
Voss, M.; Gordon, M.S.; Mita, M.; Rini, B.; Makker, V.; Macarulla, T.; Smith, D.; Kwak, E.L.; Cervantes, A.; Puzanov, I.; Pili, R.; Wang, D.; Jalal, S.; Pant, S.; Patel, M.; Neuwirth, R.; Zohren, F.; Infante, J.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S72
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A phase 1b multicenter, open-label study of investigational TAK-228 (MLN0128) plus TAK-117 (MLN1117) in adult patients with advanced nonhematologic malignancies. (December 2016)

Authors:
Juric, D.; Lopez, J.; Rasco, D.; Macarulla Mercadé, T.; Xu, Q.; Brittany, B.; Kuida, K.; Patel, C.; Neuwirth, R.; Enke, A.; Zohren, F.; Burris, H.A.
Journal:
European journal of cancer
Issue:
Volume 69(2016)supplement 1
Page Start:
S11
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search